The Combination of BH3-Mimetic ABT-737 with the Alkylating Agent Temozolomide Induces Strong Synergistic Killing of Melanoma Cells Independent of p53

Metastatic melanoma has poor prognosis and is refractory to most conventional chemotherapies. The alkylating agent temozolomide (TMZ) is commonly used in treating melanoma but has a disappointing response rate. Agents that can act cooperatively with TMZ and improve its efficacy are thus highly sough...

Descripción completa

Detalles Bibliográficos
Autores principales: Reuland, Steven N., Goldstein, Nathaniel B., Partyka, Katie A., Cooper, David A., Fujita, Mayumi, Norris, David A., Shellman, Yiqun G.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2011
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3163662/
https://www.ncbi.nlm.nih.gov/pubmed/21897876
http://dx.doi.org/10.1371/journal.pone.0024294

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3163662/
https://www.ncbi.nlm.nih.gov/pubmed/21897876
http://dx.doi.org/10.1371/journal.pone.0024294

Ejemplares similares